<DOC>
	<DOCNO>NCT01474330</DOCNO>
	<brief_summary>To evaluate safety , tolerability , pharmacokinetics pomalidomide administer orally day 5 day , daily dose 0.5 mg , 1 mg , 2 mg .</brief_summary>
	<brief_title>A Multiple-ascending-dose Study Evaluate Safety , Tolerability , Pharmacokinetics Pomalidomide ( CC-4047 ) Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Healthy male subject ethnic origin age 18 55 body mass index 19 30 1 . Any condition , include presence laboratory abnormality , psychiatric illness , would prevent subject signing Informed Consent Document ( ICD ) , place subject unacceptable risk participate study , confound ability interpret data study . 2 . Presence surgical medical condition possibly affect drug absorption , distribution , metabolism , excretion , plan elective medical procedure conduct trial . 3 . Exposure investigational drug ( new chemical entity ) within 30 day prior first dose administration 5 halflives investigational drug , know ( whichever longer ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pomalidomide</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>